Svetlana Lucas
CIK: 0001781292
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jul 31, 2026JSPR
Jasper Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy
7.5K shares- - Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
Purchase(P)Indirect3K shares at avg. $15.00$45K - Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
109.4K shares- - Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
Award(A)DirectPerformance-based Stock Option (Right to Buy)
109.4K shares- - May 11, 2026ATYR
aTYR PHARMA INC
Award(A)DirectStock Option (right to buy)
50K shares- - Mar 13, 2026SCTX
Scribe Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
9.5K shares- - Sep 22, 2025JSPR
Jasper Therapeutics, Inc.
Purchase(P)Direct20K shares at avg. $2.43$49K - Jul 3, 2025JSPR
Jasper Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
7.5K shares- - May 1, 2025ATYR
aTYR PHARMA INC
Award(A)DirectStock Option (right to buy)
50K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 31, 2026 |  JSPR Jasper Therapeutics, Inc. | Award(A) Stock Option (Right to Buy | 7,500 | - | - | Direct |
| Jul 23, 2026 |  SCTX Scribe Therapeutics, Inc. | Purchase(P) | 3,000 | $15.00 | $45,000 | Indirect |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 109,426 | - | - | Direct |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | Award(A) Performance-based Stock Option (Right to Buy) | 109,426 | - | - | Direct |
| May 11, 2026 |  ATYR aTYR PHARMA INC | Award(A) Stock Option (right to buy) | 50,000 | - | - | Direct |
| Mar 13, 2026 | SCTX Scribe Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 9,547 | - | - | Direct |
| Sep 22, 2025 | JSPR Jasper Therapeutics, Inc. | Purchase(P) | 20,000 | $2.43 | $48,600 | Direct |
| Jul 3, 2025 | JSPR Jasper Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 7,500 | - | - | Direct |
| May 1, 2025 | ATYR aTYR PHARMA INC | Award(A) Stock Option (right to buy) | 50,000 | - | - | Direct |
1-9 of 9 transactions
About Lucas Svetlana
Lucas Svetlana (SEC CIK 0001781292) files insider reports with the SEC as Director of Jasper Therapeutics, Inc. (JSPR), Chief Business Officer of Scribe Therapeutics, Inc. (SCTX) and Director of aTYR PHARMA INC (ATYR).
Signal8 holds 7 ownership filings by Lucas Svetlana (1 Form 3, 6 Form 4), filed between May 2, 2025 and Aug 4, 2026. Those filings report 9 transactions, from May 1, 2025 to Jul 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Lucas Svetlana's filings is in REDWOOD CITY, CA.
Recent filings by Lucas Svetlana
- Jul 31, 2026: Grant or award of JSPR derivative securities (Form 4, code A).
- Jul 23, 2026: Open-market purchase of SCTX shares (Form 4, code P).
- Jul 23, 2026: Grants or awards of SCTX derivative securities (2 lines, Form 4, code A).
- May 11, 2026: Grant or award of ATYR derivative securities (Form 4, code A).
- Mar 13, 2026: Grant or award of SCTX derivative securities (Form 4, code A).
Other insiders filing for Jasper Therapeutics, Inc. (JSPR)
- WIGGANS THOMAS G, Director
- Crutcher Patrick J, Director
- EMSTER KURT VON, Director
- Shizuru Judith Anne, Director
- Keenan Greg, Chief Medical Officer
- Ros Matthew E, Chief Operating Officer